Drugging MYCN through an Allosteric Transition in Aurora Kinase A

Cancer Cell

Volumn 26, Issue 3, 2014, Pages 414-427

  Gustafson, William Clay ^a,d   Meyerowitz, Justin Gabriel ^b,c,d   Nekritz, Erin A ^a,d   Chen, Justin ^b   Benes, Cyril ^f   Charron, Elise ^a,b,d   Simonds, Erin F ^b,d   Seeger, Robert ^g   Matthay, Katherine K ^a,d   Hertz, Nicholas T ^c   Eilers, Martin ^e   Shokat, Kevan M ^b,c   Weiss, William A ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f HARVARD MEDICAL SCHOOL   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ALISERTIB; AURORA A KINASE; AURORA A KINASE INHIBITOR; AURORA B KINASE; AURORA KINASE INHIBITOR; CD 532; HISTONE H3; MYC PROTEIN; PROTEASOME; PYRIMIDINE DERIVATIVE; TOZASERTIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; CD532 COMPOUND; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; ENZYME CONFORMATION; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; IC50; MEDULLOBLASTOMA; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; S PHASE CELL CYCLE CHECKPOINT; STRUCTURE ACTIVITY RELATION; ANIMAL; AREA UNDER THE CURVE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVE SITE; METABOLISM; NEUROBLASTOMA; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; SCID MOUSE; TUMOR CELL LINE; TUMOR VOLUME; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; AURORA KINASE A; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MODELS, MOLECULAR; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, SECONDARY; PROTEOLYSIS; PYRIMIDINES; S PHASE CELL CYCLE CHECKPOINTS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908689719     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.07.015     Document Type: Article

References (46)

1. Adams P.D., Afonine P.V., Bunkóczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.-W., Kapral G.J., Grosse-Kunstleve R.W., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
2. Brockmann M., Poon E., Berry T., Carstensen A., Deubzer H.E., Rycak L., Jamin Y., Thway K., Robinson S.P., Roels F., et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 2013, 24:75-89.
3. Carmena M., Ruchaud S., Earnshaw W.C. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr. Opin. Cell Biol. 2009, 21:796-805.
4. Carol H., Boehm I., Reynolds C.P., Kang M.H., Maris J.M., Morton C.L., Gorlick R., Kolb E.A., Keir S.T., Wu J., et al. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother. Pharmacol. 2011, 68:1291-1304.
5. Chanthery Y.H., Gustafson W.C., Itsara M., Persson A., Hackett C.S., Grimmer M., Charron E., Yakovenko S., Kim G., Matthay K.K., Weiss W.A. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci. Transl. Med. 2012, 4:ra3.
6. Chesler L., Schlieve C., Goldenberg D.D., Kenney A., Kim G., McMillan A., Matthay K.K., Rowitch D., Weiss W.A. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 2006, 66:8139-8146.
7. Crosio C., Fimia G.M., Loury R., Kimura M., Okano Y., Zhou H., Sen S., Allis C.D., Sassone-Corsi P. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell. Biol. 2002, 22:874-885.
8. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
9. Dietrich J., Hulme C., Hurley L.H. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. Bioorg. Med. Chem. 2010, 18:5738-5748.
10. Dodson C.A., Kosmopoulou M., Richards M.W., Atrash B., Bavetsias V., Blagg J., Bayliss R. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Biochem. J. 2010, 427:19-28.
11. Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:486-501.
12. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
13. Filomia F., De Rienzo F., Menziani M.C. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics. Bioorg. Med. Chem. 2010, 18:6805-6812.
14. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
15. Gogolin S., Ehemann V., Becker G., Brueckner L.M., Dreidax D., Bannert S., Nolte I., Savelyeva L., Bell E., Westermann F. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle 2013, 12:1091-1104.
16. Görgün G., Calabrese E., Hideshima T., Ecsedy J., Perrone G., Mani M., Ikeda H., Bianchi G., Hu Y., Cirstea D., et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010, 115:5202-5213.
17. Gustafson W.C., Weiss W.A. Myc proteins as therapeutic targets. Oncogene 2010, 29:1249-1259.
18. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth invivo. Nat. Med. 2004, 10:262-267.
19. Kenney A.M., Cole M.D., Rowitch D.H. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003, 130:15-28.
20. Kim J., Aftab B.T., Tang J.Y., Kim D., Lee A.H., Rezaee M., Kim J., Chen B., King E.M., Borodovsky A., et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013, 23:23-34.
21. Lin C.Y., Lovén J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., Lee T.I., Young R.A. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
22. Liu Q., Kaneko S., Yang L., Feldman R.I., Nicosia S.V., Chen J., Cheng J.Q. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J. Biol. Chem. 2004, 279:52175-52182.
23. Manfredi M.G., Ecsedy J.A., Chakravarty A., Silverman L., Zhang M., Hoar K.M., Stroud S.G., Chen W., Shinde V., Huck J.J., et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel invivo pharmacodynamic assays. Clin. Cancer Res. 2011, 17:7614-7624.
24. Maris J.M., Morton C.L., Gorlick R., Kolb E.A., Lock R., Carol H., Keir S.T., Reynolds C.P., Kang M.H., Wu J., et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer 2010, 55:26-34.
25. Martin M.P., Zhu J.-Y., Lawrence H.R., Pireddu R., Luo Y., Alam R., Ozcan S., Sebti S.M., Lawrence N.J., Schönbrunn E. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. ACS Chem. Biol. 2012, 7:698-706.
26. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U.S.A 2011, 108:16669-16674.
27. Mossé Y.P., Lipsitz E., Fox E., Teachey D.T., Maris J.M., Weigel B., Adamson P.C., Ingle M.A., Ahern C.H., Blaney S.M. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin. Cancer Res. 2012, 18:6058-6064.
28. Nie Z., Hu G., Wei G., Cui K., Yamane A., Resch W., Wang R., Green D.R., Tessarollo L., Casellas R., et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012, 151:68-79.
29. Nussinov R., Tsai C.-J. Allostery in disease and in drug discovery. Cell 2013, 153:293-305.
30. Osguthorpe D.J., Hagler A.T. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry 2011, 50:4105-4113.
31. Otto T., Horn S., Brockmann M., Eilers U., Schüttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
32. Ouchi M., Fujiuchi N., Saisal K., Katayama H., Minamishima Y.A., Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J. Biol. Chem. 2004, 279:19643-19648.
33. Prochownik E.V., Vogt P.K. Therapeutic targeting of Myc. Genes Cancer 2010, 1:650-659.
34. Puissant A., Frumm S.M., Alexe G., Bassil C.F., Qi J., Chanthery Y.H., Nekritz E.A., Zeid R., Gustafson W.C., Greninger P., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3:308-323.
35. Romer J.T., Kimura H., Magdaleno S., Sasai K., Fuller C., Baines H., Connelly M., Stewart C.F., Gould S., Rubin L.L., Curran T. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004, 6:229-240.
36. Scrittori L., Hans F., Angelov D., Charra M., Prigent C., Dimitrov S. pEg2 aurora-A kinase, histone H3 phosphorylation, and chromosome assembly in Xenopus egg extract. J. Biol. Chem. 2001, 276:30002-30010.
37. Shang X., Burlingame S.M., Okcu M.F., Ge N., Russell H.V., Egler R.A., David R.D., Vasudevan S.A., Yang J., Nuchtern J.G. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol. Cancer Ther. 2009, 8:2461-2469.
38. Soucek L., Whitfield J.R., Sodir N.M., Massó-Vallés D., Serrano E., Karnezis A.N., Swigart L.B., Evan G.I. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013, 27:504-513.
39. Swartling F.J., Grimmer M.R., Hackett C.S., Northcott P.A., Fan Q.-W., Goldenberg D.D., Lau J., Masic S., Nguyen K., Yakovenko S., et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010, 24:1059-1072.
40. Thomas W.D., Chen J., Gao Y.R., Cheung B., Koach J., Sekyere E., Norris M.D., Haber M., Ellis T., Wainwright B., Marshall G.M. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Oncogene 2009, 28:1605-1615.
41. Toyoshima M., Howie H.L., Imakura M., Walsh R.M., Annis J.E., Chang A.N., Frazier J., Chau B.N., Loboda A., Linsley P.S., et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc. Natl. Acad. Sci. U.S.A 2012, 109:9545-9550.
42. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997, 16:2985-2995.
43. Wen Q., Goldenson B., Silver S.J., Schenone M., Dancik V., Huang Z., Wang L.-Z., Lewis T.A., An W.F., Li X., et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 2012, 150:575-589.
44. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., Liang W.X., Song A.X., Lallemand-Breitenbach V., Jeanne M., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
45. Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A., Kirkpatrick R.B., Lai Z. Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2. Protein Sci. 2008, 17:1791-1797.
46. Zhu S., Lee J.-S., Guo F., Shin J., Perez-Atayde A.R., Kutok J.L., Rodig S.J., Neuberg D.S., Helman D., Feng H., et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012, 21:362-373.